Northern AIM VCT PLC

Northern AIM VCT PLC is a Venture Capital Trust established under the legislation introduced in the Finance Act 1995. The company’s principal objective is to invest in a portfolio consisting mainly of investments in quoted and unquoted smaller UK companies which will, through a combination of income yield and capital growth, provide high long-term returns to shareholders.

Northern AIM VCT's portfolio of VCT-qualifying investments is focused on companies quoted on the AIM market but also includes a number of later-stage unquoted holdings.

Northern AIM VCT was formed in 2000.

The company’s share price is carried daily in the Financial Times (under “Investment Companies - VCTs”), the Daily Telegraph, the Newcastle Journal and the Herald. To obtain an updated share price please click here. Share price information is provided by the London Stock Exchange plc whose terms and conditions you will be required to accept in order to view the information.

The financial calendar for the year ending 31 October 2009 is as follows:

June 2009 Half-yearly financial report for the six months ending 30 April 2009 published

December 2009 Final dividend and results for year to 31 October 2009 announced

January 2010 Annual report and accounts published

February 2010 Annual general meeting

March 2010 Final dividend paid, Annual General Meeting

Northern AIM VCT PLC is a member of the Association of Investment Companies.

If you would like to receive a copy of the latest published annual report and accounts or half-yearly financial report, by post, please contact us. If you would like to download reports in PDF format, please click here.

Directors

Registrars:

Auditors:

  • KPMG Audit Plc

Latest news

VCT for income: Northern 3 VCT 15 million share issue offer

Northern 3 VCT PLC has launched a public offer of 15 million new ordinary shares. For further information & the prospectus click here.

Abermed sold to
International SOS

NVM has sold its investment in Abermed, the UK occupational health and remote medical services company, to International SOS, the world's leading provider of integrated medical and security assistance, for an undisclosed consideration. For further information click here.

DxS sold to Qiagen –
record exit for NVM

NVM has sold DxS to Qiagen to create a global leader in personalised medicine for a value of $130 million ($95 million initial consideration plus earnouts of up to $35 million). For further information click here.